Trial Profile
A Prospective, Randomized, Controlled Pilot Study of CelTx(TM) (Apligraf) as an Alternative to Tissue From the Palate in the Treatment of Gingival Recession Requiring Root Coverage
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jun 2014
Price :
$35
*
At a glance
- Drugs Allogeneic cultured keratinocytes and fibroblasts (Primary)
- Indications Gingival disorders
- Focus Adverse reactions
- Sponsors Organogenesis
- 19 Jun 2014 New trial record